Stoke Therapeutics Inc STOK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
-
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
-
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
-
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
-
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
-
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trading Information
- Previous Close Price
- $29.37
- Day Range
- $28.58–30.14
- 52-Week Range
- $11.14–40.13
- Bid/Ask
- $28.64 / $28.81
- Shares Outstanding
- 62.28M
- Market Cap
- $1.79B
- Volume/Avg
- 184,427 / 645,469
Key Statistics
- Price/Earnings (Normalized)
- 41.33
- Price/Sales
- 55.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 170
Valuation
|
Metric
|
STOK
|
|---|---|
Price/Earnings (Normalized) | 41.33 |
Price/Book Value | 4.63 |
Price/Sales | 55.41 |
Price/Cash Flow | — |
Price/Earnings
STOK
Financial Strength
|
Metric
|
STOK
|
|---|---|
Quick Ratio | 8.57 |
Current Ratio | 8.99 |
Interest Coverage | — |
Quick Ratio
STOK
Profitability
|
Metric
|
STOK
|
|---|---|
Return on Assets (Normalized) | −33.66% |
Return on Equity (Normalized) | −38.93% |
Return on Invested Capital (Normalized) | −42.71% |
Return on Assets
STOK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Hmvgpbvt | Ghbnrk | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cwnpbsnvq | Pywpypy | $65B | |||
| argenx SE ADR
ARGX
| Yxlfxtshl | Vfw | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jkjzwqfc | Kpfddws | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Gdxnsdvxz | Wkfyfzv | $25B | |||
| BioNTech SE ADR
BNTX
| Rpwkdkz | Wlf | $22B | |||
| Incyte Corp
INCY
| Gszbrtxr | Wrxn | $21B | |||
| Moderna Inc
MRNA
| Cgvbrkw | Vfd | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Dpsyrqplw | Mhbd | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Kkbqzpm | Vwwk | $13B |
United States